Sonoma Pharmaceuticals, Inc.
$2.65
▼
-2.47%
2026-04-21 09:31:01
sonomapharma.com
NCM: SNOA
Explore Sonoma Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.59 M
Current Price
$2.65
52W High / Low
$6.92 / $2
Stock P/E
—
Book Value
$1.98
Dividend Yield
—
ROCE
-38.66%
ROE
-81.18%
Face Value
—
EPS
$-1.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8
Beta
1.76
Debt / Equity
19.09
Current Ratio
2.88
Quick Ratio
2.38
Forward P/E
-4.07
Price / Sales
0.22
Enterprise Value
$2.04 M
EV / EBITDA
-0.78
EV / Revenue
0.12
Rating
None
Target Price
$12
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biofrontera Inc. | $1.09 | — | $12.81 M | — | -68.08% | -1.41% | $1.19 / $0.54 | $0.9 |
| 2. | China Pharma Holdings, Inc. | $0.67 | — | $26.84 M | — | -46.43% | -20.91% | $2.6 / $0.5 | $1.47 |
| 3. | Kiniksa Pharmaceuticals International, plc | $42.46 | 55.07 | $3.25 B | — | 12.37% | 11.73% | $50.03 / $19.62 | $7.44 |
| 4. | Anika Therapeutics, Inc. | $15.82 | — | $213.74 M | — | -6.56% | -6.71% | $16.02 / $7.87 | $10.33 |
| 5. | Collegium Pharmaceutical, Inc. | $34.31 | 17.33 | $1.09 B | — | 14.67% | 23.7% | $50.79 / $25.86 | $9.51 |
| 6. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 7. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 4.35 M | 5.6 M | 4.01 M | 3.75 M | 3.56 M | — |
| Operating Profit | -0.68 M | -0.34 M | -1.09 M | -0.66 M | -1.03 M | — |
| Net Profit | -0.82 M | -0.53 M | -1.24 M | -0.78 M | -0.93 M | — |
| EPS in Rs | -0.47 | -0.31 | -0.72 | -0.45 | -0.54 | -0.59 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 14.29 M | 12.73 M | 13.27 M | 12.63 M |
| Operating Profit | -3.71 M | -4.7 M | -4.57 M | -5.89 M |
| Net Profit | -3.46 M | -4.83 M | -5.15 M | -5.09 M |
| EPS in Rs | -2 | -2.79 | -2.98 | -2.94 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 13.69 M | 14.74 M | 16.23 M | 18.84 M |
| Total Liabilities | 9.28 M | 8.6 M | 8.25 M | 10.15 M |
| Equity | 4.41 M | 6.14 M | 7.98 M | 8.7 M |
| Current Assets | 12.65 M | 12.55 M | 13.8 M | 16.43 M |
| Current Liabilities | 4.1 M | 3.72 M | 3.72 M | 5.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -0.09 M | -2.4 M | -6.15 M | -4.25 M |
| Investing CF | -0.08 M | -0 M | -0.26 M | -0.1 M |
| Financing CF | 3.03 M | 1.68 M | 2.49 M | 7.4 M |
| Free CF | -0.17 M | -2.4 M | -6.42 M | -4.38 M |
| Capex | -0.08 M | -0 M | -0.27 M | -0.14 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 12.19% | -4.05% | 5.1% | — |
| Earnings Growth % | 28.5% | 6.13% | -1.28% | — |
| Profit Margin % | -24.2% | -37.97% | -38.81% | -40.28% |
| Operating Margin % | -25.97% | -36.91% | -34.43% | -46.62% |
| Gross Margin % | 38.25% | 37.26% | 33.73% | 31.62% |
| EBITDA Margin % | -25% | -35.53% | -33.49% | -45.15% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-30 | 1:0.05 |